Suggestions

Du même auteur

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

Archive ouverte | Rodon, P. | CCSD

International audience

Safe and prolonged survival with Long-term exposure to Pomalidomide in Relapsed/Refractory Myeloma

Archive ouverte | Fouquet, G. | CCSD

International audience. Background - The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40%...

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Archive ouverte | Chrétien, M. | CCSD

International audience

Chargement des enrichissements...